New technique for identifying small molecules may speed up drug discovery, manufacturing

A UCLA-led team of scientists has developed a new technique that will enable researchers to easily and quickly determine the structures of organic molecules using very small samples. The work is already drawing significant attention in the scientific community: A preview of the paper that was posted on the website ChemRxiv was downloaded 19,000 times in 24 hours, shattering the site's previous record of 15,000 downloads in six months.

The final paper, which was published in ACS Central Science, describes a new method for using electron microscopes to examine small molecules. The approach enables scientists to analyze nanocrystals, which are so small that they can only be seen using special electron microscopes, and identify them within about 30 minutes, instead of the several hours that the current process takes.

Christopher Jones, a UCLA chemistry and biochemistry graduate student and the study's lead author, said the fact that the process works so well with "small" molecules -- those that are composed of only a few hundred atoms or less, as opposed to "large" ones, which can be made up of hundreds of thousands -- is significant because small molecules are key ingredients to the overwhelming majority of pharmaceuticals on the market today. The molecules' extra-small size allows them to more easily penetrate tightly packed cell membranes to reach their targets in the body.

In addition, Jones said, the new process can work with "vanishingly small" quantities of sample. Previously, for scientists using X-rays, the same type of information could only be gleaned from samples the size of a grain of sand. With electron microscopy, samples one-millionth or even one-billionth that size can be used.

"Using this technique, the speed at which we can formulate potentially life-saving drugs will be greatly accelerated," said Hosea Nelson, a UCLA assistant professor of chemistry and biochemistry and a senior author of the research. "It will be like going from riding a tricycle to driving a Ferrari."

Ultimately, the technique could accelerate processes for drug development because pharmaceutical companies would be able to screen more samples faster than ever before, which would reduce the time it takes to verify the molecular structure of potential drugs.

Among the words of praise from scientists and media:

  • "'Astounded,' 'blown away,' 'astonished.' Has there been another recent example in #chemistry of people going so nuts about a new advance?" Lila Guterman, deputy news editor, Science Magazine, on Twitter
  • "Very few papers in recent times have made me sit up and do a double take, but this one did. At one point the authors say they were 'astounded' by the ease of the technique, and I don't think that word is out of place at all." The Curious Wavefunction blog
  • "'I am blown away by this,' says Carolyn Bertozzi, a chemist at Stanford University. "The fact that you can get these structures from [a sample] a million times smaller than a speck of dust, that's beautiful. It's a new day in chemistry." Science Magazine
  • "To see an over-the-counter cold and flu medicine capsule being cracked open and the heterogeneous powder inside analyzed at atomic-level resolution is awesome. Even if this technique only works for a subset of organic small molecules, what is shown in these papers is stunning."UC Berkeley chemist Tom Maimone in Chemical & Engineering News
  • "Another absolutely incredible advance in #cryo-EM promises to speed our ability to determine the atomic structure of small molecules that are key to biological discovery and #drug development." National Institutes of Health Director Francis S. Collins on Twitter

"As chemists, we typically devote so much time to interpreting complex spectral data to identify our compounds," Jones said. "While developing this technique, I was amazed at how rapidly we could obtain high resolution, unambiguous chemical structures of organic molecules."

Christopher G Jones, Michael W Martynowycz, Johan Hattne, Tyler J Fulton, Brian M Stoltz, Jose A Rodriguez, Hosea M Nelson, Tamir Gonen.
The CryoEM Method MicroED as a Powerful Tool for Small Molecule Structure Determination.
ACS Cent. Sci., 2018, 4 (11), pp 1587-1592. doi: 10.1021/acscentsci.8b00760.

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...